Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Innovative Clinical Trial Design: Commercial vs Open-Source Software? Why Not Both?

In the ever-changing field of clinical trial design, there is often a need to evaluate design options quickly and efficiently. But when it comes to evaluating options, which is better: commercial or open-source software? And does it need to be a question of either-or?

Read full article

Perspectives on Enquiry and Evidence

September 2, 2022

Summer Weekend Read Roundup

Last week, we featured our final Summer Weekend Read, the last in a series designed to showcase some of our most recent...

Read article

August 12, 2022

The Model-Based Approach: A Better Way to Forecast Enrollment

Read article

May 23, 2018

Addressing Critical Unmet Oncology Needs in the Era of Precision Medicine

Our Industry Voices series showcases our clients’ innovative work and breakthrough therapeutics in oncologic...

Read article

May 16, 2018

Rewriting the oncology textbook with cell-based immunotherapies

Our Industry Voices series showcases our clients’ innovative work and breakthrough therapeutics in oncologic...

Read article

May 9, 2018

Innovative Oncology Trial Designs in Practice

As we prepare to head to ASCO in under a month's time, we are pleased to share a new ebook that showcases some key...

Read article

July 26, 2017

Are Adaptive Designs the Answer to Oncology Development Success?

Sadly, clinical development of anti-cancer therapeutics faces particularly high rates of failure, even in the context...

Read article

April 11, 2017

FDA 22 Case Studies and Mitigating Phase 3 Risks

In a January 2017 paper (1), the FDA reviewed 22 case studies where promising Phase 2 trials did not result in...

Read article

March 10, 2017

Flexible approaches to Biosimilars Development

At the recent Biosimilars Summit in Philadelphia, Cytel's Pantelis Vlachos presented on statistical challenges and...

Read article

March 2, 2017

Case Study: Bayesian Decision-Making in a Phase 3 Oncology Design

We continue our case study series with this example of a Phase 3 design that uses Bayesian decision making combined...

Read article

February 9, 2017

Inside an Oncology Statistician's Toolkit

In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses in...

Read article

December 2, 2016

Innovative Phase 3 Adaptive Enrichment Design in Oncology

At a recent Pfizer/ Cytel seminar on rare disease and oncology development, Cytel’s Lingyun Liu presented innovative...

Read article

October 11, 2016

Simulations to optimize clinical trial programs

Its important to take a strategic approach to clinical development in order to minimize the potential for Phase 3...

Read article

September 27, 2016

Practical Challenges of the LUNG-MAP study

The Lung-MAP trial is an innovative biomarker driven 'precision medicine' study which evaluates five novel agents for...

Read article

September 13, 2016

Case Study:Exposure Response Modeling in Hematology

Exposure-response data gained from clinical studies can provide a basis for model-based analysis and simulation,...

Read article

September 9, 2016

Case Study:Seamless Phase 2/3 Design in Rare Disease

Challenge: Our client, an emerging biotechnology company, was preparing for the next stage of development for their...

Read article

July 18, 2016

Adaptive Design in the limelight with NEJM article

In order for adaptive designs to reach their potential, it’s critical that knowledge is effectively dissemirnated...

Read article

April 5, 2016

What's the price of pharma innovation?

Cost of pharmaceutical development and R&D productivity is an ongoing industry concern, consistently discussed in the...

Read article

May 20, 2015

Seamless Adaptive Clinical Trials: What’s really at stake?

Seamless adaptive clinical trials have gained popularity for reducing the projected time it takes to complete the...

Read article

January 20, 2015

Why Drugs Fail in Phase 3: A Cytel Infographic

According to a recent Cytel Whitepaper on Adaptive Clinical Trials, 50% of Phase 3 trials eventually fail. This new...

Read article